003220.KS KSC
Daewon Pharmaceutical Co., Ltd.
1W: +0.5%
1M: -1.0%
3M: -1.4%
YTD: -32.9%
1Y: -39.8%
3Y: -40.0%
5Y: -46.9%
₩7,890.00 ($5.88)
+0.00 (+0.00%)
Weekly Expected Move ±2.0%
₩7573
₩7732
₩7890
₩8048
₩8207
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$613.7B
+5.2% ▲
5Y CAGR: +12.9%
Total Liabilities
$335.2B
+12.2% ▲
5Y CAGR: +22.3%
Shareholders Equity
$265.9B
-3.4% ▼
5Y CAGR: +4.4%
Cash & Investments
$76.5B
+65.9% ▲
5Y CAGR: +48.7%
Total Debt
$187.1B
-0.1% ▼
5Y CAGR: +28.9%
Net Debt
$139.9B
-17.8% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $41.7B | $27.0B | $30.0B | $17.1B | $47.2B |
| Short-Term Investments | $13.1B | $20.0B | $48M | $29.1B | $29.3B |
| Cash & ST Investments | $54.8B | $47.0B | $30.0B | $46.1B | $76.5B |
| Net Receivables | $54.6B | $66.9B | $70.6B | $77.9B | $80.4B |
| Inventory | $69.7B | $91.8B | $105.1B | $113.2B | $97.8B |
| Other Current Assets | $3.4B | $5.5B | $3.1B | $18.3B | $53M |
| Total Current Assets | $180.4B | $207.3B | $209.3B | $257.6B | $256.6B |
| Property, Plant & Equip. | $166.7B | $158.9B | $160.1B | $208.4B | $222.9B |
| Goodwill & Intangibles | $40.4B | $40.1B | $41.5B | $54.8B | $62.5B |
| Long-Term Investments | $15.0B | $16.4B | $89.1B | $19.6B | $59.2B |
| Other Non-Current Assets | $17.5B | $24.2B | $23M | $34.5B | $45M |
| Total Non-Current Assets | $249.2B | $246.3B | $298.7B | $325.8B | $357.0B |
| Total Assets | $429.6B | $453.6B | $508.0B | $583.4B | $613.7B |
| — Liabilities — | |||||
| Accounts Payable | $17.2B | $19.6B | $20.9B | $20.9B | $30.3B |
| Short-Term Debt | $51.4B | $62.1B | $109.5B | $119.0B | $117.1B |
| Deferred Revenue | $33.1B | $4.7B | $0 | $0 | $21.9B |
| Other Current Liabilities | $29.4B | $36.1B | $46.3B | $30.8B | $46.6B |
| Total Current Liabilities | $102.1B | $128.1B | $182.7B | $200.8B | $216.3B |
| Long-Term Debt | $69.6B | $52.1B | $34.6B | $63.6B | $67.9B |
| Other Non-Current Liab. | $36.9B | $23.6B | $25.6B | $31.5B | $48.9B |
| Total Non-Current Liabilities | $109.1B | $76.6B | $61.0B | $98.0B | $118.9B |
| Total Liabilities | $211.2B | $204.8B | $243.7B | $298.8B | $335.2B |
| — Equity — | |||||
| Common Stock | $10.6B | $11.0B | $11.1B | $11.2B | $11.2B |
| Retained Earnings | $204.8B | $241.6B | $255.8B | $16.0B | -$8.0B |
| Accumulated OCI | $197.2B | $198.4B | $0 | $0 | $259.8B |
| Total Stockholders Equity | $219.3B | $250.9B | $266.2B | $275.3B | $265.9B |
| Total Liabilities & Equity | $429.6B | $453.6B | $508.0B | $583.4B | $613.7B |
| — Key Metrics — | |||||
| Total Debt | $124.0B | $116.5B | $146.0B | $187.2B | $187.1B |
| Net Debt | $82.3B | $89.5B | $116.1B | $170.2B | $139.9B |
| Total Investments | $28.1B | $36.4B | $89.2B | $48.6B | $88.5B |